CN118340787A — 药物
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2024-07-16 · 2y expired
What this patent protects
本发明提供用于预防或治疗肺高血压的药物。用于预防或治疗肺高血压的药物,其含有选自以下的化合物:(5R)‑N‑[1‑乙基‑1‑(4‑乙基苯基)丙基]‑2,7,7‑三甲基‑5‑苯基‑4,5,6,7‑四氢吡唑并[1,5‑a]嘧啶‑3‑羧酰胺、(5R)‑N‑[1‑乙基‑1‑(4‑甲氧基苯基)丙基]‑2,7,7‑三甲基‑5‑苯基‑4,5,6,7‑四氢吡唑并[1,5‑a]嘧啶‑3‑羧酰胺、(5R)‑N‑[1‑乙基‑1‑(4‑乙基苯基)丙基]‑5‑(2‑氟苯基)‑2,7,7‑三甲基‑4,5,6,7‑四氢吡唑并[1,5‑a]嘧啶‑3‑羧酰胺、及它们的盐。
USPTO Abstract
本发明提供用于预防或治疗肺高血压的药物。用于预防或治疗肺高血压的药物,其含有选自以下的化合物:(5R)‑N‑[1‑乙基‑1‑(4‑乙基苯基)丙基]‑2,7,7‑三甲基‑5‑苯基‑4,5,6,7‑四氢吡唑并[1,5‑a]嘧啶‑3‑羧酰胺、(5R)‑N‑[1‑乙基‑1‑(4‑甲氧基苯基)丙基]‑2,7,7‑三甲基‑5‑苯基‑4,5,6,7‑四氢吡唑并[1,5‑a]嘧啶‑3‑羧酰胺、(5R)‑N‑[1‑乙基‑1‑(4‑乙基苯基)丙基]‑5‑(2‑氟苯基)‑2,7,7‑三甲基‑4,5,6,7‑四氢吡唑并[1,5‑a]嘧啶‑3‑羧酰胺、及它们的盐。
Drugs covered by this patent
- Opsumit (MACITENTAN) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.